Hematogenous histoplasmosis in the immunocompromised child.
Hematogenous (disseminated) histoplasmosis occurred in 31 of 4158 children with cancer or immune deficiency disorders. Approximately half of the 31 patients had pulmonary lesions, reacted to the histoplasmin skin test, and generated complement-fixing antibodies to Histoplasma capsulatum. In a comparative study delayed hypersensitivity to histoplasmin was demonstrated in 36 (5.7%) of 634 children at the time of diagnosis of cancer. Patients with cancer who were reactive to histoplasmin before treatment were at no greater, and possibly less, risk for hematogenous histoplasmosis than were nonreactors. All of the 27 patients who received treatment for greater than 1 day recovered; three had recurrences that responded to treatment.
D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006660:Histoplasmosis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D012306:Risk
D000970:Antineoplastic Agents; D000666:Amphotericin B; D007654:Ketoconazole